Novo Nordisk (NVO) CEO says Trump administration's straightforward approach has made deal-making easier, via JP Morgan conference

• Still fighting against compounded versions of Wegovy. 
• Compounders of GLP-1 drugs read the consumer better than the pharma industry did, compounders of GLP-1 may have 1.5ln patients in the US. 

Novo Nordisk's CEO highlighted how the Trump administration's straightforward deal-making approach simplifies negotiations in the pharmaceutical sector. This context could indicate a more favorable environment for M&A in healthcare, potentially impacting sentiment toward related equities and affecting currency flows, especially as the company navigates challenges in its GLP-1 drug segment.